Kegan Liyan oral liquid ameliorates lipopolysaccharide-induced acute lung injury through inhibition of TLR4-mediated NF-κB signaling pathway and MMP-9 expression

详细信息    查看全文

• 作者：Xie Zhang^a ; ^e ; ¹ ; ^{985958620@qq.com" class="auth_mail" title="E-mail the corresponding author} ; Chao-Yue Sun^a ; ^e ; ¹ ; ^{936316352@qq.com" class="auth_mail" title="E-mail the corresponding author} ; Yong-Bin Zhang^a ; ^{yongbinzhang@gzucm.edu.cn" class="auth_mail" title="E-mail the corresponding author} ; Hui-Zhen Guo^c ; ^{604041882@qq.com" class="auth_mail" title="E-mail the corresponding author} ; Xue-Xuan Feng^d ; ^{345375526@qq.com" class="auth_mail" title="E-mail the corresponding author} ; Shao-Zhong Peng^b ; ^{691789232@qq.com" class="auth_mail" title="E-mail the corresponding author} ; Jie Yuan^a ; ^e ; ^{466754442@qq.com" class="auth_mail" title="E-mail the corresponding author} ; Rong-Bo Zheng^b ; ^{zrbb0819@sina.com" class="auth_mail" title="E-mail the corresponding author} ; Wei-Ping Chen^b ; ^{Chenwp@gpc.com.cn" class="auth_mail" title="E-mail the corresponding author} ; Zi-Ren Su^a ; ^e ; ^{suziren@gzucm.edu.cn" class="auth_mail" title="E-mail the corresponding author} ; Xiao-Dan Huang^b ; ^{xiaodanhuang@126.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：KGLY ; Kegan Liyan Oral Liquid ; LPS ; Lipopolysaccharide ; ALI ; Acute Lung Injury ; BALF ; Bronchoalveolar Lavage Fluid ; W/D ; Lung Wet/Dry Ratio ; IL-1β ; Interleukin-1β ; IL-6 ; Interleukin-6 ; TNF-α ; Necrosis Factor-α ; MIP-2 ; Macrophage Inflammatory Protein-2 ; SOD ; Superoxide Dismutase ; GSH ; Glutathione ; MPO ; Myeloperoxidase ; MDA ; Malondialdehyde ; TLR4 ; Toll-like Receptor 4 ; NF-κB ; Nuclear Factor Kappa B ; MMP-9 ; Matrix Metalloproteinases 9 ; ARDS ; Acute Respiratory Distress Syndrome ; TCM ; Traditional Chi
• 刊名：Journal of Ethnopharmacology
• 出版年：2016
• 出版时间：20 June 2016
• 年：2016
• 卷：186
• 期：Complete
• 页码：91-102
• 全文大小：2993 K

文摘

Kegan Liyan oral liquid (KGLY), a Chinese prescription modified from classic formulas Yin-Qiao-San (from TCM classic Wenbing Tiaobian) and Shen-Jie-San (first mentioned in Shanghan Wenyi Tiaobian), has been reported to exert heat-clearing and detoxifying effects and used extensively for the treatment of severe pulmonary diseases in clinics including influenza, cough and pneumonia.

Aim of this study

The purpose of this study was to investigate the protective effect of KGLY on lipopolysaccharide (LPS) induced acute lung injury (ALI) in mice and to illuminate the underlying mechanisms.

Materials and methods

Mice were orally administrated with KGLY (50, 100 and 150 mg/kg) before intratracheal instillation of LPS. 24 h post LPS challenge, lung tissues and the bronchoalveolar lavage fluid (BALF) were collected for lung wet/dry (W/D) weight ratio, histopathological examinations and biochemical analyses. The cell counts, protein concentration, interleukin-1β (IL-1β), interleukin-6 (IL-6), necrosis factor-α (TNF-α), macrophage inflammatory protein-2 (MIP-2) in BALF, superoxide dismutase (SOD), glutathione (GSH), myeloperoxidase (MPO) and malondialdehyde (MDA) levels were detected. Meanwhile, the activation of toll-like receptor 4 (TLR4), nuclear factor kappa B (NF-κB), as well as matrix metalloproteinases 9 (MMP-9) were determined by western blot assay.

Results

KGLY significantly prolonged mice survival time and ameliorated LPS-induced edema, thickening of alveolar septa and inflammatory cell infiltration in a dose-dependent manner. Additionally, KGLY markedly attenuated LPS-induced acute pulmonary inflammation via decreasing the expressions of cytokines and chemokines (IL-1β, IL-6, TNF-α, and MIP-2), enhanced the activities of anti-oxidative indicators (SOD and GSH), suppressed the levels of MPO and MDA, and down-regulated the expressions of TLR4, NF-κB and MMP9.

Conclusions

The results suggested that the relieving effect of KGLY against LPS-induced ALI might be partially due to suppression of oxidative stress and inflammatory response, inhibition of TLR4-mediated NF-κB activation, and down-regulation of MMP9 expression, indicating it may be a potential therapeutic agent for ALI.